RESULTS: Of 128 LCA patients (75 female, 53 male), mean age was 63 (30-83) years and BMI was 31.3kg/m2. Median ASA score was 3. Comorbidities included: hypertension (82/128), renal insufficiency (33/128), diabetes (28/128), ischemic cardiac disease (17/128) and solitary kidney (11/128). RP approach was used in 30/78 right vs 38/65 left-sided tumors with TP in the remainder. Mean tumor size was 3.0 (+/-1.1) cm and surgical time was 211.1 (+/-63.4) min. Two freeze cycles were performed in 97/143 tumors and mean freeze cycle duration was 11.0 (+/-8.3) min. Mean EBL was 164.6mL and postop discharge was 24 hrs and 48 hrs in 45/133 and 84/133 of cases, respectively. Average hematocrit and eGFR change from pre-to postop was -5.1 mg/dL and 3.96 mL/min/1.73m2, respectively. Intraoperative biopsy (n¼143) showed malignancy in 97 (67.8%) or oncocytic neoplasm in 21 (14.7%) cases. Of the remainder, 18 were benign (12.6%) and 6 were angiomyolipoma (4.2%). One sample was lost. Surgical limitations to tumor treatment were noted in only 3/143 (2.1%) tumors using our LCA technique. Of patients with biopsy-proven renal cancer or oncocytic neoplasm, 113/118 (95.8%) had no tumor persistence (mean radiologic follow-up 49.4 (+/-28.4) months (0.4-131.8 months)). Only 7/128 (5.5%) patients had recurrence.
INTRODUCTION AND OBJECTIVES: The optimal approach for a renal tumor in a solitary kidney is unknown. Our objective was to compare outcomes between partial nephrectomy (PN) and percutaneous cryoablation (PCA) for tumors in a solitary kidney.
METHODS: Patients with a solitary kidney undergoing PN or PCA for a single localized primary renal tumor between 2005-2015 were identified using Mayo Clinic Registries. Exclusions were inherited tumor syndromes, multiple tumors, and salvage procedures. To achieve balance in baseline characteristics, inverse probability of treatment weighting (IPTW) was employed using propensity scores computed based on age, Charlson co-morbidity index, treatment year, nephrometry score, tumor size, baseline estimated glomerular filtration rate (eGFR), confirmed renal cell carcinoma (RCC) histology, and history of prior contralateral nephrectomy for RCC. Complications (Clavien scale), renal function outcomes, local recurrence, distant metastasis, and cancer-specific survival were compared between groups using logistic, linear, and Fine-and-Gray competing risks regression modeling.
RESULTS: The cohort included 118 patients (PN: 64; PCA: 54) with a median follow-up of 48 months (IQR 23, 80) . In unadjusted analyses, PCA was associated with a decreased risk of complications (15% vs 31%; OR¼0.4; 95%CI 0.2-1.0; p¼0.04). However, upon accounting for baseline differences with IPTW-adjustment, there was no longer a significant difference in risk of complications (26% vs 27%; OR¼1.0; 95%CI 0.4-2.2; p¼0.9). Higher nephrometry score was associated with greater risk of complications for both PN (OR[per 1 point]¼1.5; 95%CI 1.1-2.0; p¼0.01) and PCA (OR[per 1 point]¼1.7; 95%CI 1.0-2.9; p¼0.04), but nephrometry score did not modify the effect of treatment modality on the risk of complications (p-interaction¼0.17). Median percentage drop in eGFR from baseline to 3 months from treatment was 16% and 7% for PCA and PN, respectively (p¼0.23). There were no significant differences between PCA and PN in risk of local recurrence (HR¼1.0; 95%CI 0.3-3.4; p>0.9), distant metastasis (HR¼0.7; 95%CI 0.2-1.9; p¼0.5), or cancerspecific mortality (HR¼1.4; 95%CI 0.2-8.0; p¼0.7).
CONCLUSIONS: Both PN and PCA appear to be viable options for renal tumors in solitary kidneys. Although PCA was associated with fewer complications in unadjusted analyses, there were no significant differences between PCA and PN, regardless of tumor complexity, when adjusting for treatment selection bias. Short term oncologic outcomes appear similar although additional follow-up is needed.
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LONG-TERM OUTCOMES OF CRYOABLATION FOR BIOPSY-PROVEN RCC: SIZE MATTERS Sara Best, Brett Johnson*, Shane Wells, Meghan Lubner, Timothy Ziemlewicz, J. Louis Hinshaw, Fred Lee, Stephen Y Nakada, E. Jason Abel, Madison, WI INTRODUCTION AND OBJECTIVES: Cryoablation (CA) is an alternative treatment for small renal cell carcinomas (RCC), although some prior studies lack biopsy data or long term follow-up. We sought to identify risk factors for treatment failure of biopsy-proven RCC following CA as primary treatment at a single institution.
METHODS: Comprehensive data were reviewed for 89 patients with biopsy-proven T1 renal cancer who underwent CA as primary treatment between 2003 -2012. The Kaplan Meier method was used to estimate recurrence-free survival (RFS) from the date of treatment to recurrence, progression, or most recent imaging. A multivariable Cox model was used to evaluate associations with survival.
RESULTS: All tumors were biopsy proven RCC and 62/89 (70%) were clear cell subtype. Median tumor size was 2.6 cm (IQR 2.1 -3.1) and median follow-up was 50.7 months ). Overall 5-year survival was 48/57 (82%). Five-year cancer specific survival was 56/57 (98%). Five-year RFS was 89.1% overall. Of 10 CA failures, 9 (90%) tumors recurred locally and 1 progressed to metastatic disease. Mean tumor size among the successful treatment group was 2.63 cm versus 3.28 cm for the treatment failure group (p ¼ 0.05) and all failures were clear cell subtype (p < 0.05). Secondary treatments included: repeat ablation 7/10, nephrectomy 2/10 and systemic therapy 1/10. On Cox multivariate analyses, increased risk of recurrence was associated with tumor diameter (HR ¼ 1.751, p ¼ 0.01). Age, BMI, creatinine, presence of solitary kidney, and history of previous ablation were not associated with recurrence. Median time until recurrence for tumors 3.0 cm was 9.9 months and 18.1 months for tumors <3.0 cm, (p ¼ 0.38).
CONCLUSIONS: Cryotherapy provides durable treatment of RCC smaller than 4cm. Success of treatment inversely correlates to tumor size. Most treatment failures were successfully treated with repeat ablation. Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1337
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